TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21281234

Group type: EXPERIMENTAL
Intervention: GM-ELISA- and Aspergillus PCR-driven antifungal therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fever-driven empiric antifungal treatment strategy
Number of subjects: 0
Study: 21281486

Group type: EXPERIMENTAL
Intervention: Real-time RT-PCR assay for EpCAM detection in peripheral blood preoperatively and postoperatively (D1B, D7B, 6WB)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Real-time RT-PCR assay for EpCAM detection in peritoneal lavage fluid preoperatively and postoperatively
Number of subjects: 58
Study: 21281521

Group type: EXPERIMENTAL
Intervention: Meeting ≥ 1 dietary, sedentary, or PA recommendations
Number of subjects: 92

Group type: COMPARATOR
Intervention: Not meeting any behavioral recommendations
Number of subjects: 92
Study: 21281873

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (age-matched and sex-matched)
Number of subjects: 20
Study: 21282185

Group type: EXPERIMENTAL
Intervention: Injection drug use
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Sexual transmission
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: HCV identical strain clusters
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Men who have sex with men
Number of subjects: 163
Study: 21282484

Group type: EXPERIMENTAL
Intervention: Patients with PAH (REVEAL)
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with idiopathic PAH and those with PAH associated with drugs and toxins
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of patients with PAH associated with congenital heart disease, connective tissue disease, and human immunodeficiency virus
Number of subjects: 2141

Group type: COMPARATOR
Intervention: NHANES normal comparison group
Number of subjects: 2141
Study: 21282578

Group type: COMPARATOR
Intervention: Electroretinogram (ERG) pattern responses, b-wave in the scotopic bright flash ERG, a-wave and b-wave in the photopic single-flash ERG, oscillatory potential responses
Number of subjects: 28

Group type: COMPARATOR
Intervention: Vascular response to flicker light
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Flicker light-induced arterial retinal vasodilation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Neural and neurovascular dysfunctions
Number of subjects: 28
Study: 21283743

Group type: EXPERIMENTAL
Intervention: Laboratory abnormalities based on non-indigenous laboratory references
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Medical abnormalities
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Laboratory reference intervals developed from East and Southern Africa
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Eligible participants
Number of subjects: 281
Study: 21284479

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with microdialysis-based subcutaneous glucose monitoring system
Number of subjects: 20
Study: 21284837

Group type: EXPERIMENTAL
Intervention: Surgery or lifestyle intervention (specifics not provided)
Number of subjects: 133
Study: 21284880

Group type: EXPERIMENTAL
Intervention: Canadian C-Spine Rule
Number of subjects: 3000
Study: 21285134

Group type: EXPERIMENTAL
Intervention: Neoadjuvant CAPOX (capecitabine-oxaliplatin) plus bevacizumab
Number of subjects: 46
Study: 21287306

Group type: EXPERIMENTAL
Intervention: Candida spp. in respiratory tract cultures
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bacterial pathogens in respiratory tract cultures
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Culture negative
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group with no clinical suspicion of VAP
Number of subjects: 100
Study: 21288612

Group type: EXPERIMENTAL
Intervention: Whey protein supplement (WPS) 60 g/day for 4 weeks
Number of subjects: 11
Study: 21289257

Group type: EXPERIMENTAL
Intervention: Oral water load
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 3% saline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of vasopressin and copeptin concentrations
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of plasma osmolality with copeptin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Correlation of plasma osmolality with vasopressin
Number of subjects: 20
Study: 21289369

Group type: EXPERIMENTAL
Intervention: Sunitinib (second line treatment)
Number of subjects: 51
Study: 21292087

Group type: EXPERIMENTAL
Intervention: Intraperitoneal microdialysis (MD)
Number of subjects: 12
Study: 21292758

Group type: EXPERIMENTAL
Intervention: Nonwhite patients
Number of subjects: 3138
Study: 21292991

Group type: EXPERIMENTAL
Intervention: Low-level exercise (30 W) in LVSD patients
Number of subjects: 60
Study: 21293089

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg daily for 4 weeks, with an option to increase to 10 mg at week 4 (both studies) and week 8 (VOLT)
Number of subjects: 2645

Group type: COMPARATOR
Intervention: Tolterodine extended release 4 mg for ≥ 4 weeks prior to solifenacin
Number of subjects: 2645

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 2645
Study: 21293986

Group type: EXPERIMENTAL
Intervention: Hard drug use (cocaine, amphetamines, or heroin)
Number of subjects: 643
Study: 21294601

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 551
Study: 21296274

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) as salvage treatment after prostatic radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0
Study: 21296508

Group type: EXPERIMENTAL
Intervention: Extended-release zolpidem
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21296811

Group type: EXPERIMENTAL
Intervention: Implanted active epiretinal array
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Retina underlying the array
Number of subjects: 1

Group type: COMPARATOR
Intervention: Normal patients (control group)
Number of subjects: 1
Study: 21296824

Group type: EXPERIMENTAL
Intervention: Visual Awareness and Eccentric Viewing (module 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Control of Reading Eye Movements (module 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reading Practice with Sequential Presentation of Lexical Information (module 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study: 21298520

Group type: EXPERIMENTAL
Intervention: Hybrid VATS sleeve lobectomy
Number of subjects: 148
Study: 21299393

Group type: EXPERIMENTAL
Intervention: BD GGBP sensor (intradermal placement)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BD GGBP sensor (subcutaneous placement)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GOx-based sensor
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BD GGBP sensor
Number of subjects: 40
Study: 21299450

Group type: EXPERIMENTAL
Intervention: Eating pathology class
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Low psychopathology class
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intermediate psychopathology class
Number of subjects: 125
Study: 21299922

Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) initial test
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) retest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) initial test and retest scores
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) items
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sino-Nasal Outcome Test 22 (SNOT-22) subscales
Number of subjects: 40
Study: 21300307

Group type: EXPERIMENTAL
Intervention: Baroreflex activation therapy (BAT) using an implanted device (Rheos)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21300462

Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT)
Number of subjects: 30
Study: 21300566

Group type: EXPERIMENTAL
Intervention: Adjuvanted HIV-1 vaccine candidate
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Elecsys HIV Combi assay
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ADVIA Centaur EHIV
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PRISM HIV O Plus assay
Number of subjects: 50
Study: 21300924

Group type: EXPERIMENTAL
Intervention: Oral vorinostat (200 mg twice daily on days 1-14 of a 21-day cycle)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral vorinostat
Number of subjects: 35
Study: 21301463

Group type: EXPERIMENTAL
Intervention: Double-contrast ultrasound
Number of subjects: 0
Study: 21304070

Group type: EXPERIMENTAL
Intervention: Ultrasmall superparamagnetic particles of iron oxide (USPIO) administered before and 24 to 36 hours after MRI imaging
Number of subjects: 29

Group type: COMPARATOR
Intervention: No USPIO uptake
Number of subjects: 29

Group type: COMPARATOR
Intervention: Nonspecific USPIO uptake
Number of subjects: 29
Study: 21304982

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted pH1N1 vaccine (Focetria®, Novartis) administered twice
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 2009-2010 seasonal TIV
Number of subjects: 58
Study: 21306210

Group type: EXPERIMENTAL
Intervention: Inflammatory and neuroendocrine biomarkers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical decision-making based on biomarkers
Number of subjects: 0
Study: 21306793

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring with vagal nerve stimulation
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring
Number of subjects: 390
Study: 21308151

Group type: EXPERIMENTAL
Intervention: Givinostat (ITF 2357), an orally active HDAC inhibitor, administered for 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified, but implied comparison to standard treatments like methotrexate and anticytokines.
Number of subjects: 0
Study: 21310317

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1820
Study: 21310379

Group type: EXPERIMENTAL
Intervention: Tear osmolarity
Number of subjects: 314

Group type: COMPARATOR
Intervention: Corneal staining
Number of subjects: 314

Group type: COMPARATOR
Intervention: Conjunctival staining
Number of subjects: 314

Group type: COMPARATOR
Intervention: Meibomian gland grading
Number of subjects: 314

Group type: COMPARATOR
Intervention: Tear film break-up time
Number of subjects: 314

Group type: COMPARATOR
Intervention: Schirmer test
Number of subjects: 314
Study: 21310866

Group type: EXPERIMENTAL
Intervention: Oral supplementation with pyridoxine hydrochloride (40 mg/d) for 1 month
Number of subjects: 3035

Group type: EXPERIMENTAL
Intervention: Low plasma PLP
Number of subjects: 3035
Study: 21310912

Group type: EXPERIMENTAL
Intervention: Diffuse-trickling GA phenotype
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non diffuse-trickling GA
Number of subjects: 36
Study: 21311383

Group type: EXPERIMENTAL
Intervention: Intravenous Magnesium Sulphate
Number of subjects: 0
Study: 21311694

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMMC) infusion after granulocyte colony-stimulating factor administration.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMMC cell therapy
Number of subjects: 0
Study: 21311985

Group type: EXPERIMENTAL
Intervention: Interstitial radiofrequency surgery of the soft palate (single session)
Number of subjects: 74
Study: 21314962

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Number of subjects: 0
Study: 21317257

Group type: EXPERIMENTAL
Intervention: O157 STEC strains
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: non-O157 STEC strains
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: non-O157 biofilm-producing isolates
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: O157 strains
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: non-O157 strains
Number of subjects: 51
Study: 21317503

Group type: EXPERIMENTAL
Intervention: Various recruitment strategies
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Incentives and follow-up mechanisms
Number of subjects: 45
Study: 21319147

Group type: EXPERIMENTAL
Intervention: Patient-level intervention (patient decision aid and stage-targeted brochures mailed to members)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Patient-level intervention (adjusted for baseline differences)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Patient-level intervention (for participants with incomes >$50,000)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Patient-level intervention (for participants with lower incomes)
Number of subjects: 443
Study: 21320355

Group type: EXPERIMENTAL
Intervention: Cetuximab and IMRT/carbon ion boost (18 GyE carbon ions in 6 fractions and 54 Gy IMRT at 2.0 Gy/fraction)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 49
Study: 21320979

Group type: EXPERIMENTAL
Intervention: anti-inflammatory treatment
Number of subjects: 0
Study: 21321062

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1 mg/d) for 8 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low folate diet for 12 weeks followed by folic acid repletion (1 mg/d) for 4 weeks
Number of subjects: 10
Study: 21324375

Group type: EXPERIMENTAL
Intervention: 1 dose of AS03-adjuvanted H1N1 influenza vaccine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 2 doses of AS03-adjuvanted H1N1 influenza vaccine
Number of subjects: 17
Study: 21325343

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25[OH]D < 20 ng/mL)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Individuals who were vitamin D deficient at baseline but no longer deficient at follow-up
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Increases in 25(OH)D to greater than or equal to 20 ng/mL
Number of subjects: 368
Study: 21328719

Group type: EXPERIMENTAL
Intervention: Haloperidol (first generation antipsychotic)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olanzapine (second generation antipsychotic)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 60
Study: 21329725

Group type: EXPERIMENTAL
Intervention: Tenofovir discontinuation
Number of subjects: 0
Study: 21330384

Group type: EXPERIMENTAL
Intervention: Better septal function
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Septal strain from -18% to -10%
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Septal function
Number of subjects: 917

Group type: EXPERIMENTAL
Intervention: Interventricular septal function
Number of subjects: 917
Study: 21330400

Group type: EXPERIMENTAL
Intervention: Categorization of continuous variables
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of data-derived 'optimal' cut-points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Application of results from a registry on unruptured intracranial aneurysms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous explanatory variables
Number of subjects: 0
Study: 21330601

Group type: EXPERIMENTAL
Intervention: mCSCs isolated from endomyocardial biopsies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: vCSCs isolated from endomyocardial biopsies
Number of subjects: 0

Group type: COMPARATOR
Intervention: mCSCs and vCSCs isolated from endomyocardial biopsies
Number of subjects: 0
Study: 21330625

Group type: EXPERIMENTAL
Intervention: Cognitive impairment no dementia (CIND)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: CIND-mild and CIND-moderate
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: CIND-moderate
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Visuomotor speed impairment
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: CIND severity
Number of subjects: 419

Group type: COMPARATOR
Intervention: No independent predictors
Number of subjects: 419
Study: 21330656

Group type: EXPERIMENTAL
Intervention: Method A (eye tracker and retest function engaged)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Method B (without eye tracker and retest function)
Number of subjects: 103
Study: 21333027

Group type: EXPERIMENTAL
Intervention: Integrative health care model (IHCM) involving a family doctor, nurse, psychologist, and the woman herself, lasting three months with a three-month follow-up period.
Number of subjects: 0
Study: 21333082

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) program for 6 weeks
Number of subjects: 0
Study: 21334018

Group type: EXPERIMENTAL
Intervention: High intensity focused ultrasound hemiablation
Number of subjects: 20
Study: 21334404

Group type: EXPERIMENTAL
Intervention: rs738409 polymorphism in ALD patients
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: PNPLA3 mRNA liver expression level in ALD patients
Number of subjects: 330
Study: 21334562

Group type: EXPERIMENTAL
Intervention: Indiscriminately social/disinhibited RAD
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Emotionally withdrawn/inhibited RAD
Number of subjects: 129
Study: 21334595

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab injected monthly for one year
Number of subjects: 10
Study: 21338429

Group type: EXPERIMENTAL
Intervention: Asthma subjects (smokers, ex-smokers, never-smokers)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal smokers
Number of subjects: 59
Study: 21338641

Group type: EXPERIMENTAL
Intervention: Sorafenib (800 mg/d) plus metronomic tegafur/uracil (250 mg/m(2)/d)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Sorafenib plus tegafur/uracil
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: K(trans) change after treatment
Number of subjects: 31
Study: 21339701

Group type: EXPERIMENTAL
Intervention: Menveo® (MenACWY-CRM; Novartis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Menactra® (MCV4; sanofi pasteur)
Number of subjects: 0
Study: 21342518

Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviors by 25%
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviors by 50%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Baseline sedentary behavior
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Reducing sedentary behaviors
Number of subjects: 55
Study: 21343560

Group type: EXPERIMENTAL
Intervention: RUNX1 mutations
Number of subjects: 945

Group type: COMPARATOR
Intervention: Allogeneic hematopoietic stem-cell transplantation
Number of subjects: 945
Study: 21343760

Group type: EXPERIMENTAL
Intervention: Multiple marker test using four markers (progesterone, VEGF, inhibin A, activin A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Individual biomarkers (inhibin A, progesterone, activin A, VEGF, pregnancy-specific β-1-glycoprotein, pregnancy-associated plasma protein-A)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Additional six markers
Number of subjects: 200
Study: 21344317

Group type: EXPERIMENTAL
Intervention: Fragmented QRS (fQRS) at the 48th hour after primary PCI (group 1)
Number of subjects: 85

Group type: COMPARATOR
Intervention: No fragmented QRS (group 2)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: fQRS
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Q wave
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: QRS distortion
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Duration of chest pain
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: fQRS at 48th hour
Number of subjects: 85
Study: 21344495

Group type: EXPERIMENTAL
Intervention: PFDI short form
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: PFIQ short form
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: PFDI-20 urinary scale
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: PFDI-20 prolapse scale
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: PFDI-20 colorectal scale
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: PFIQ-7 scales
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: SF-36 (or SF-12) summary scores
Number of subjects: 1006
Study: 21345642

Group type: EXPERIMENTAL
Intervention: CMV-seronegative plus leukoreduced blood products
Number of subjects: 1300
Study: 21345726

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg) and Bortezomib (1.6 mg/m2)
Number of subjects: 63
Study: 21346617

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study: 21349464

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 3388
Study: 21349999

Group type: EXPERIMENTAL
Intervention: Brivanib (800 mg orally once daily)
Number of subjects: 55
Study: 21350030

Group type: EXPERIMENTAL
Intervention: Revision total hip arthroplasty (THA) with acetabular bone impaction grafting
Number of subjects: 20

Group type: COMPARATOR
Intervention: Primary total hip arthroplasty (THA)
Number of subjects: 20
Study: 21350210

Group type: EXPERIMENTAL
Intervention: Partial aortic occlusion after thrombolysis
Number of subjects: 22
Study: 21352516

Group type: EXPERIMENTAL
Intervention: Web-enabled mobile phone intervention with daily online entries and individualized written feedback
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Web-enabled mobile phone intervention
Number of subjects: 6
Study: 21352561

Group type: EXPERIMENTAL
Intervention: Rituximab (Mabthera®) combined with involved field radiotherapy (30 - 40 Gy)
Number of subjects: 85
Study: 21352601

Group type: EXPERIMENTAL
Intervention: 200 mg orally administered AS (artesunate)
Number of subjects: 51
Study: 21354816

Group type: EXPERIMENTAL
Intervention: Electromagnetic tracking and multimodality image fusion guidance for biopsy and RF ablation procedures
Number of subjects: 40
Study: 21355002

Group type: EXPERIMENTAL
Intervention: Belotecan (CKD 602) at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Number of subjects: 16
Study: 21355077

Group type: EXPERIMENTAL
Intervention: Langerhans cell (LC) vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: monocyte-derived dendritic cell (moDC) vaccines
Number of subjects: 0
Study: 21355087

Group type: EXPERIMENTAL
Intervention: Doxorubicin 25 mg/m(2), vinblastine 6 mg/m(2), and gemcitabine 800 mg/m(2) (1000 mg/m(2) in first 6) on days 1 and 15 every 28 days for 6 cycles
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cycle 2 PET-negative patients
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cycle 2 PET-positive patients
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cycle 6 PET-negative patients
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cycle 6 PET-positive patients
Number of subjects: 99